NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
SN BioScience
Incyte Corporation
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Cyteir Therapeutics, Inc.
Sellas Life Sciences Group
Vincerx Pharma, Inc.
AstraZeneca
Xencor, Inc.
Advaxis, Inc.
Cancer Research and Biostatistics Clinical Trials Consortium
Exelixis
Memorial Sloan Kettering Cancer Center
Fate Therapeutics
Xencor, Inc.
Xencor, Inc.
Incyte Corporation
AbbVie
AbbVie
Incyte Corporation
Gilead Sciences
Spectrum Pharmaceuticals, Inc
Incyte Corporation
Abramson Cancer Center at Penn Medicine
Celgene
PharmaMar
Daiichi Sankyo
Swiss Cancer Institute
Pfizer
Masonic Cancer Center, University of Minnesota
University of Kansas Medical Center
Amgen
Roswell Park Cancer Institute
Amgen
Santa Maria Biotherapeutics
Dana-Farber Cancer Institute
Novartis
M.D. Anderson Cancer Center
University of Southern California
Fox Chase Cancer Center
Case Comprehensive Cancer Center
ImmunoGen, Inc.
Memorial Sloan Kettering Cancer Center
INSYS Therapeutics Inc
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC